<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3322">
  <stage>Registered</stage>
  <submitdate>14/10/2011</submitdate>
  <approvaldate>14/10/2011</approvaldate>
  <nctid>NCT01454284</nctid>
  <trial_identification>
    <studytitle>A Study in Patients With Type I Diabetes Mellitus</studytitle>
    <scientifictitle>The Impact of LY2605541 Versus Insulin Glargine for Patients With Type 1 Diabetes Mellitus Treated With Preprandial Insulin Lispro: a Double-Blind, Randomized, 52-week Study</scientifictitle>
    <utrn />
    <trialacronym>IMAGINE 3</trialacronym>
    <secondaryid>I2R-MC-BIAO</secondaryid>
    <secondaryid>12147</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Diabetes Mellitus, Type 1</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Glargine
Treatment: drugs - LY2605541
Treatment: drugs - Insulin Lispro

Experimental: LY2605541 + Insulin Lispro - LY2605541 titrated based on blood glucose readings, administered subcutaneously once daily at bedtimes for 52 weeks in combination with Insulin Lispro. Insulin Lispro titrated based on blood glucose readings, administered subcutaneously at meal times for 52 weeks.

Active Comparator: Glargine + Insulin Lispro - Glargine dose titrated based on blood glucose readings, administered subcutaneously once daily at bedtimes for 52 weeks in combination with Insulin Lispro. Insulin Lispro dose titrated based on blood glucose readings, administered subcutaneously at meal times for 52 weeks.


Treatment: drugs: Glargine
Administered by subcutaneous injection

Treatment: drugs: LY2605541
Administered by subcutaneous injection.

Treatment: drugs: Insulin Lispro
Administered subcutaneously

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Hemoglobin A1c (HbA1c)</outcome>
      <timepoint>52 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Rate of total hypoglycemia events</outcome>
      <timepoint>0 to 26 weeks, 0 to 52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of participants with HbA1c equal or less than 6.5% and less than 7.0 %</outcome>
      <timepoint>26 weeks, 52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Fasting serum glucose (by laboratory measurement)</outcome>
      <timepoint>26 weeks, 52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>9 point self-monitored blood glucose (SMBG)</outcome>
      <timepoint>26 weeks, 52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in body weight</outcome>
      <timepoint>Baseline, 26 weeks, 52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline to 52 weeks in HbA1c</outcome>
      <timepoint>Baseline, 26 weeks, 52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Basal, meal time, and total insulin dose per body weight</outcome>
      <timepoint>26 weeks, 52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>European Quality of Life -5 dimension (EuroQol-5 dimension)</outcome>
      <timepoint>52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Insulin Treatment Satisfaction Questionnaire</outcome>
      <timepoint>52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adult Low Blood Sugar Survey</outcome>
      <timepoint>26 weeks, 52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Triglycerides, low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C)</outcome>
      <timepoint>Baseline, 26 weeks, 52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in anti-LY2605541 antibodies</outcome>
      <timepoint>Baseline, 26 weeks, 52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Intra-patient variability of fasting blood glucose (FBG)</outcome>
      <timepoint>26 weeks, 52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of total hypoglycemic events</outcome>
      <timepoint>0-26 weeks, 0-52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of participants with HbA1c less than 7.0 % and without nocturnal hypoglycemia</outcome>
      <timepoint>26 weeks, 52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Rapid Assessment of Physical Activity (RAPA)</outcome>
      <timepoint>26 weeks, 52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Fasting blood glucose (by participant self monitored blood glucose readings)</outcome>
      <timepoint>26 weeks, 52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of nocturnal hypoglycemic events</outcome>
      <timepoint>0-26 weeks, 0-52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hemoglobin A1c (HbA1c)</outcome>
      <timepoint>26 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>0300 hours blood glucose (BG) to fasting BG excursion</outcome>
      <timepoint>26 weeks, 52 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Type 1 diabetes for at least 1 year

          -  HbA1c value less than 12 percent according to the central laboratory at screening

          -  body mass index of less than or equal to 35.0 kg/m^2

          -  Have been treated for at least 90 days prior to screening with

               -  insulin detemir, insulin glargine, or Neutral Protamine Hagedorn (NPH)in
                  combination with pre-meal insulin, or

               -  self mixed or pre-mixed insulin regimens with any basal and bolus insulin
                  combination administered at least twice daily, or

               -  continuous subcutaneous insulin infusion therapy

          -  Women who are not breast feeding and test negative for pregnancy before receiving
             treatment and agree to use reliable birth control until 4 weeks after last treatment
             with study drug

          -  Are capable and willing to adhere to multiple daily injections, inject with a vial and
             syringe and prefilled pen and perform self monitored blood glucose readings and record
             keeping</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Are using twice daily insulin glargine having been inadequately controlled on single
             daily dose of glargine prior to screening

          -  Excessive insulin resistance defined as having received a total daily dose of insulin
             greater than 1.5 U/kg at the time of randomization

          -  Receiving any oral or injectable medication (other than insulins or metformin for
             treatment of polycystic ovarian disease) intended for the treatment of diabetes
             mellitus in the 90 days prior to screening

          -  Lipid lowering medications:

               -  are using niacin preparations as lipid lowering medication and/or bile acid
                  sequestrants within 90 days prior to screening; or,

               -  are using lipid lowering medication at a dose that has not been stable for 90
                  days or more prior to screening

               -  Have fasting hypertriglyceridemia (defined as greater than 4.5 mmol/L, greater
                  than 400 mg/dl) at screening, as determined by the central laboratory.

               -  Have had more than 1 episode of severe hypoglycemia within 6 months prior to
                  screening

               -  Have had 2 or more emergency room visits or hospitalizations due to poor glucose
                  control within 6 months prior to screening

               -  Have cardiac disease with functional status that is New York Heart Association
                  Class III or IV

               -  Have a history of renal transplantation or are currently receiving renal dialysis
                  or have serum creatinine greater than 2.5 mg/dL

               -  Have obvious clinical signs or symptoms of liver disease (excluding non-alcoholic
                  fatty liver disease [NAFLD]), acute or chronic hepatitis, non alcoholic
                  steatohepatitis (NASH), or elevated liver enzyme measurements as indicated below:

               -  total bilirubin 2 times or more than the upper limit of normal (ULN) as defined
                  by the central laboratory, or

               -  alanine aminotransferase (ALT)/(serum glutamic pyruvic transaminase (SGPT) more
                  than 2.5 times ULN as defined by the central laboratory, or

               -  aspartate aminotransferase (AST)/(serum glutamic oxaloacetic transaminase (SGOT)
                  more than 2.5 times ULN as defined by the central laboratory

               -  Have active or untreated malignancy, have been in remission from clinically
                  significant malignancy (other than basal cell or squamous cell skin cancer) for
                  less than 5 years, or are at increased risk for developing cancer or a recurrence
                  of cancer

               -  Diagnosed clinically significant diabetic autonomic neuropathy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>1113</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/02/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,SA,VIC</recruitmentstate>
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Merewether</hospital>
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Keswick</hospital>
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Box Hill</hospital>
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Parkville</hospital>
    <postcode>2291 - Merewether</postcode>
    <postcode>5035 - Keswick</postcode>
    <postcode>3128 - Box Hill</postcode>
    <postcode>3050 - Parkville</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Hawaii</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Idaho</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Iowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Montana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nevada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Hampshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Edegem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Huy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Sint-Niklaas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Fortaleza</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Porto Alegre</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>São Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Manitoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Nova Scotia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Croatia</country>
      <state>Osijek</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Kobenhavn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>La Rochelle</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Le Creuzot</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Rouen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Athens</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Chalkida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Thessaloniki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Dublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Haifa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Jerusalem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Petah Tikva</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Petah Tiqva</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel Hashomer</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Lithuania</country>
      <state>Jonava</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Lithuania</country>
      <state>Kaunas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Dordrecht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Groningen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Wellington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Gdansk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Katowice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Krakow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lubin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Szczecin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warsaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Sturovo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Houghton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Pretoria</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Somerset West</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Alcala De Henares</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Alcira</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Málaga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Sevilla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Seville</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Alingsås</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Helsingborg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Huddinge</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Karlstad</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Avon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Hampshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Lancashire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Leicestershire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Scotland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Suffolk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Surrey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Wales</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Glasgow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Northampton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Oxford</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Eli Lilly and Company</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Boehringer Ingelheim</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is:

        -  To compare the blood sugar control on LY2605541 with insulin glargine after 52 weeks of
           treatment.

        -  To compare the number of nocturnal low blood sugar episodes on LY2605541 with insulin
           glargine during 52 weeks of treatment.

        -  To compare the number of patients on LY2605541 reaching blood sugar targets without low
           blood sugar episodes at night to those taking insulin glargine after 52 weeks of
           treatment.

        -  To compare the total number of low blood sugar episodes on LY2605541 with insulin
           glargine after 52 weeks of treatment</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01454284</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</name>
      <address>Eli Lilly and Company</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>